Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
about
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromesHigh management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumoursOutpatient therapeutic nuclear oncology.ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.Renal function affects absorbed dose to the kidneys and haematological toxicity during ¹⁷⁷Lu-DOTATATE treatmentSomatostatin receptor based imaging and radionuclide therapy.Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors.Evaluation of retinol binding protein 4 and carbamoylated haemoglobin as potential renal toxicity biomarkers in adult mice treated with (177)Lu-octreotateA multimodal approach to the management of neuroendocrine tumour liver metastasesThe Challenges of Treating Paraganglioma Patients with (177)Lu-DOTATATE PRRT: Catecholamine Crises, Tumor Lysis Syndrome and the Need for Modification of Treatment ProtocolsLong-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide.Molecular theranostics: a primer for the imaging professionalOptimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies.MIA PaCa-2 and PANC-1 - pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors.Malignant neuroendocrine tumour of the gallbladder with elevated carcinoembryonic antigen: case report and literature review.IMPROVED PLANAR KIDNEY ACTIVITY CONCENTRATION ESTIMATE BY THE POSTERIOR VIEW METHOD IN 177LU-DOTATATE TREATMENTS.Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis.May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET? A pilot report on (188)Re-HEDP treatment in progressive bone metastases after (177)Lu-octreotate.Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrThe prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy: Case report and review of literatureRadiometallated peptides for molecular imaging and targeted therapy.New therapeutic options for metastatic malignant insulinomas.ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas.Radionuclide therapy via SSTR: future aspects from experimental animal studies.Targeting the somatostatin receptor in pituitary and neuroendocrine tumors.Review article: the investigation and management of gastric neuroendocrine tumours.Ileal neuroendocrine tumors and heart: not only valvular consequences.Long-term outcomes of (131)Iodine mIBG therapy in metastatic gastrointestinal pancreatic neuroendocrine tumours: single administration predicts non-responders.Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour.Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside.PET imaging of tumours with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate.Menin and JunD regulate gastrin gene expression through proximal DNA elements.Time-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: A simulation study on the effect of sampling schedule and noise.Preclinical evaluation of radiolabeled DOTA-derivatized cyclic minigastrin analogs for targeting cholecystokinin receptor expressing malignancies.Peptide receptor radionuclide therapy (PRRT) with [(177)Lu-DOTA(0),Tyr(3)]octreotate in combination with RAD001 treatment: further investigations on tumor metastasis and response in the rat pancreatic CA20948 tumor model.Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.Management of the hormonal syndrome of neuroendocrine tumors.Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors.
P2860
Q24603675-45485131-2A1D-4DE3-9DF0-75A332CE19D1Q28260008-533E0B42-218A-4A6B-BCD2-23B58BCBBF97Q34244990-CFC9FCAF-665B-45CF-A855-95328B5BF4DDQ34248487-80DD1F20-BC9E-4A51-8E8F-B6883C567623Q34477028-18E56AB1-AE9D-495C-9E8E-2AE129462A5DQ35244181-408674B9-8CC0-45F7-B61B-891EAB335CF6Q35296661-441B529D-7D4E-41B2-8B15-320BA00D5A63Q35675435-B49B2092-1501-486B-A22D-46BEDCA1B2C2Q35675510-8CF0A65F-A456-46EB-AB0B-7706DDAC0CBEQ35810562-799CC0C1-EF62-4760-8D0A-78A182228D44Q35941125-68B6A6DD-E541-49F0-923E-B7FCB5E05D8AQ35999552-71724F85-D2B8-45FB-BC86-8C468311F87CQ36251545-A174BC22-0B59-4E13-8C14-30262E9601A0Q36265194-F1BF339D-77D6-45BB-A209-FBA72FD8CC46Q36588574-32CFE27C-127E-4A64-964B-B5BA344744AAQ36893968-2A1EFBF2-E5AB-4619-A627-D0C9FD43D8D0Q37016021-876F2D7F-68CC-4E3A-B805-355C1424C11FQ37201458-836DFC4E-C7B8-487A-99B3-0733A2F192FFQ37402627-9BD0E5E5-C344-40A4-AC1B-F210306453A8Q37425156-53C8A4F4-C2F8-4773-8C62-AA727B1B2EEBQ37646677-FBBE83DC-4E9C-4253-A667-EDCE193C8B38Q37847064-FB327777-9B09-47BA-84F2-7B0A9C9A7D23Q37886036-078816C1-3608-4F29-A4D5-542E06606A83Q37977337-839CF58E-D61A-4268-8366-7AE868C9A976Q38008839-49533ED6-24D2-46EA-81BB-8F3DDE2D89B9Q38132768-099A70DF-EB12-4881-81E8-E8EA8E49C8F6Q38195905-B9524F1F-68CB-4C84-8566-9BAF9D4C2A9EQ38260542-3D86178F-1BA9-4FD3-BF0B-EAD12B1B7BAEQ38542762-FB053387-EE63-48FE-B30B-325F67EB2AA3Q38936576-87B6FCB5-9D9E-4470-BEFF-9CB04B2A2913Q38965866-2454CA40-07C7-41D8-A402-A56C31A1416EQ39066068-43C6959D-D80E-446B-9133-4E7B8141CA76Q39235890-DBB2BB8C-2393-40F0-A4EE-0DFCE346E316Q39430065-097549DF-93FE-4D69-B596-F02CAE2CD955Q39512185-E45EB4AC-3790-4ED8-B44B-E59CF6A2F410Q41143314-1FEC6AEC-00C4-4747-AEE9-9EA36FC4155DQ41161125-8B10275B-8342-49BC-9AEC-54DE285C0570Q41832570-A1A855C8-4D12-4DBE-BDA7-263375E84D39Q42345704-EDBF61AA-0D23-4D8B-8C8E-CE028BF3DC73Q42548064-4FE93D68-FE97-461C-804E-7B1302A5E450
P2860
Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Peptide receptor radionuclide ...... creatic neuroendocrine tumors.
@ast
Peptide receptor radionuclide ...... creatic neuroendocrine tumors.
@en
Peptide receptor radionuclide ...... creatic neuroendocrine tumors.
@nl
type
label
Peptide receptor radionuclide ...... creatic neuroendocrine tumors.
@ast
Peptide receptor radionuclide ...... creatic neuroendocrine tumors.
@en
Peptide receptor radionuclide ...... creatic neuroendocrine tumors.
@nl
prefLabel
Peptide receptor radionuclide ...... creatic neuroendocrine tumors.
@ast
Peptide receptor radionuclide ...... creatic neuroendocrine tumors.
@en
Peptide receptor radionuclide ...... creatic neuroendocrine tumors.
@nl
P2093
P1476
Peptide receptor radionuclide ...... creatic neuroendocrine tumors.
@en
P2093
Boen L Kam
Casper H J van Eijck
Dik J Kwekkeboom
Eric P Krenning
Jaap J M Teunissen
Martijn van Essen
P356
10.1053/J.SEMNUCLMED.2009.10.004
P577
2010-03-01T00:00:00Z